0000000000428545

AUTHOR

Christine Solbach

showing 10 related works from this author

Prognostic Influence of Pre-Operative C-Reactive Protein in Node-Negative Breast Cancer Patients

2014

The importance of inflammation is increasingly noticed in cancer. The aim of this study was to analyze the prognostic influence of pre-operative serum C-reactive protein (CRP) in a cohort of 148 lymph node-negative breast cancer patients. The prognostic significance of CRP level for disease-free survival (DFS), metastasis-free survival (MFS) and overall survival (OS) was evaluated using univariate and multivariate Cox regression, also including information on age at diagnosis, tumor size, tumor grade, estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) status, proliferation index (Ki67) and molecular subtype, as well as an assessment of the…

PathologyProliferation indexReceptor ErbB-2lcsh:MedicineEstrogen receptorGastroenterologyMetastasisCohort StudiesBasic Cancer ResearchBreast TumorsMedicine and Health SciencesMedicineNeoplasm Metastasislcsh:ScienceImmune ResponseAged 80 and overUnivariate analysisMultidisciplinarybiologyCancer Risk FactorsHazard ratioObstetrics and GynecologyMiddle AgedPrognosisGene Expression Regulation NeoplasticC-Reactive ProteinOncologyReceptors EstrogenFemaleReceptors ProgesteroneResearch ArticleCancer Predisposing Conditions and SyndromesAdultmedicine.medical_specialtyImmunologyBreast NeoplasmsDisease-Free SurvivalBreast cancerInternal medicineBreast CancerHumansImmune EvasionAgedCell ProliferationProportional Hazards ModelsInflammationGenome Humanbusiness.industryProportional hazards modelGene Expression Profilinglcsh:RC-reactive proteinImmunityBiology and Life SciencesCancers and NeoplasmsCancermedicine.diseaseKi-67 Antigenbiology.proteinWomen's Healthlcsh:QClinical ImmunologyLymph NodesbusinessPLoS ONE
researchProduct

Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study…

2013

Abstract Background We evaluated the pathological complete response (pCR) rate after neoadjuvant epirubicin, (E) cyclophosphamide (C) and docetaxel containing chemotherapy with and without the addition of bevacizumab in patients with triple-negative breast cancer (TNBC). Patients and methods Patients with untreated cT1c-4d TNBC represented a stratified subset of the 1948 participants of the HER2-negative part of the GeparQuinto trial. Patients were randomized to receive four cycles EC (90/600 mg/m2; q3w) followed by four cycles docetaxel (100 mg/m2; q3w) each with or without bevacizumab (15 mg/kg; q3w) added to chemotherapy. Results TNBC patients were randomized to chemotherapy without (n =…

OncologyAdultmedicine.medical_specialtyBevacizumabCyclophosphamideAnthracyclinePaclitaxelmedicine.medical_treatmentTriple Negative Breast NeoplasmsAntibodies Monoclonal HumanizedYoung AdultBreast cancerInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAnthracyclinesEverolimusCyclophosphamideAgedEpirubicinUltrasonographySirolimusChemotherapyTaxanebusiness.industryCarcinoma Ductal BreastHematologyMiddle Agedmedicine.diseaseNeoadjuvant TherapyTumor BurdenBevacizumabTreatment OutcomeOncologyDocetaxelChemotherapy AdjuvantMultivariate AnalysisFemalebusinessmedicine.drugEpirubicinAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update

2021

Geburtshilfe und Frauenheilkunde 81(10), 1112-1120 (2021). doi:10.1055/a-1499-8431

medicine.medical_specialtyAxillary lymph nodesBreast surgerymedicine.medical_treatmentMammakarzinomBreast cancerbreast cancerMaternity and MidwiferyAdjuvant therapymedicineddc:610GebFra ScienceStage (cooking)Sentinel-Lymphknoten-Entfernungtargeted axillary dissectionsentinel LNEneoadjuvante Chemotherapiebusiness.industryObstetrics and Gynecologymedicine.diseaseRadiation therapyDissectionAxillamedicine.anatomical_structuregezielte axilläre DissektionRadiologybusinessRecommendation/Empfehlungneoadjuvant chemotherapy
researchProduct

Prospective randomized comparison of conventional instruments and the Harmonic Focus(®) device in breast-conserving therapy for primary breast cancer.

2011

Abstract Background In recent years, surgeons have utilized Harmonic instruments to perform breast cancer resection. Retrospective and prospective studies have demonstrated that the use of this surgical device for mastectomy and axillary dissection can reduce perioperative blood loss, seroma formation, and duration and total amount of drainage. No study has analyzed the feasibility of Harmonic instruments in breast-conserving surgery. We conducted a prospective, randomized clinical trial comparing Harmonic instrument and conventional surgery in the performance of breast-conserving surgery and axillary procedures to determine differences in surgical procedures, postoperative outcome, and com…

Adultmedicine.medical_specialtymedicine.medical_treatmentUltrasonic TherapyBreast NeoplasmsMastectomy SegmentalRisk AssessmentStatistics Nonparametriclaw.inventionBreast cancerPostoperative ComplicationsRandomized controlled triallawGermanymedicineBreast-conserving surgeryHumansNeoplasm InvasivenessProspective StudiesProspective cohort studyAgedNeoplasm StagingPostoperative CareAcademic Medical CentersChi-Square Distributionbusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseSurgical InstrumentsSurvival AnalysisSurgeryLogistic ModelsSeromaTreatment OutcomeOncologySeromaMultivariate AnalysisSurgeryFemaleNeoplasm Recurrence LocalComplicationbusinessChi-squared distributionMastectomyFollow-Up StudiesEuropean journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
researchProduct

Prognostic significance of the chemokine CXCL13 in node-negative breast cancer

2013

615 Background: The chemokine CXCL13 is chemotactic for B cells. We examined the prognostic significance of CXCL13 mRNA expression in node-negative breast cancer. Methods: Microarray based gene-expression data for CXCL13 (205242_at) were analysed in four previously published cohorts (Mainz, Rotterdam, Transbig, Yu) of node-negative breast cancer patients not treated with adjuvant therapy (n=824). A meta-analysis of previously published cohorts was performed using a random effects model. Prognostic significance of CXCL13 on metastasis-free survival (MFS) was examined in the whole cohort and in different molecular subtypes (ER+/HER2-, ER-/HER2-, HER2+). Independent prognostic relevance was a…

OncologyCancer Researchmedicine.medical_specialtyChemokineMicroarraybiologybusiness.industryMrna expressionObstetrics and GynecologyChemotaxismedicine.diseaseNode negativeBreast cancerOncologyInternal medicineMaternity and MidwiferyImmunologyCancer researchbiology.proteinMedicineCXCL13businessGeburtshilfe und Frauenheilkunde
researchProduct

Ki-67 as an independent prognostic factor in an unselected cohort of patients with ovarian cancer: results of an explorative, retrospective study.

2013

The identification of prognostic markers has clinical implications in epithelial ovarian carcinoma (EOC). Here, we studied markers for proliferation (Ki-67), endocrine regulation [progesterone receptor (PR), estrogen receptor (ER)], and invasion [urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor (PAI-1)]. All patients with available follow-up information and EOC tissue, who were treated at our institution between 1997 and 2004, were enrolled in the present study. Expression of Ki-67, PR and ER was determined by immunohistochemical analyses. uPA and PAI-1 antigen levels were determined using enzyme‑linked immunosorbent assays. One hundred and eight patients enter…

OncologyCancer Researchmedicine.medical_specialtyCarcinoma Ovarian EpithelialDisease-Free SurvivalCohort StudiesInternal medicineProgesterone receptorPlasminogen Activator Inhibitor 1medicineBiomarkers TumorHumansNeoplasms Glandular and EpithelialProspective cohort studyCell ProliferationRetrospective StudiesUrokinaseOvarian Neoplasmsbiologybusiness.industryProportional hazards modelHazard ratioCancerGeneral MedicineMiddle Agedmedicine.diseaseUrokinase-Type Plasminogen ActivatorTumor BurdenKi-67 AntigenOncologyReceptors EstrogenKi-67biology.proteinFemalebusinessOvarian cancerReceptors Progesteronemedicine.drugOncology reports
researchProduct

Evaluation of the methodological quality of articles on autologous breast reconstruction

2018

Abstract Background Breast cancer remains the most common cancer among women worldwide. Autologous breast reconstruction may contribute toward restoring body image and improving quality of life after mastectomy. This systematic literature review describes differences in the quality and type of studies investigating autologous breast reconstruction techniques over time. Methods MEDLINE was searched for articles related to the surgical techniques, namely, TRAM, LADO, DIEP, and SGAP/IGAP, for the periods 1970 to 2007 and 2008 to 2010. The quality and type of studies were compared across the two time periods. Full-texts were evaluated according to prespecified quality criteria. Results The MEDL…

medicine.medical_specialtyMammaplastymedicine.medical_treatmentMEDLINEBreast Neoplasms030230 surgeryTransplantation Autologous03 medical and health sciences0302 clinical medicineBreast cancerQuality of lifemedicineHumansMethodological qualityMastectomybusiness.industrymedicine.diseaseChecklistSurgerySystematic review030220 oncology & carcinogenesisFemaleSurgeryPeriodicals as TopicbusinessBreast reconstructionMastectomyJournal of Plastic, Reconstructive & Aesthetic Surgery
researchProduct

Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2)

2021

Abstract Background The GAIN-2 trial was designed to identify a superior intense dose-dense (idd) strategy for high-risk patients with early breast cancer. Here, we report an interim analysis, at which the predefined futility boundary was crossed. Patients and methods GAIN-2 was an open-label, randomised, multicentre phase III trial. Two thousand eight hundred and eighty seven patients were randomised 1:1 between three courses each of idd epirubicin (E) 150 mg/m2, nab-paclitaxel (nP) 330 mg/m2 and cyclophosphamide (C) 2000 mg/m2 (iddEnPC) versus four cycles of leucocyte nadir-based tailored and dose-dense EC (dtEC) followed by four cycles of tailored and dose-dense docetaxel (dtD) (dtEC-dtD…

AdultCancer Researchmedicine.medical_specialtyTime FactorsAdolescentPaclitaxelCyclophosphamideDose-dense chemotherapymedicine.medical_treatmentBreast NeoplasmsDocetaxelRisk AssessmentDisease-Free SurvivalYoung AdultRisk FactorsAlbuminsGermanyInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProspective StudiesAdverse effectCyclophosphamideAgedEpirubicinChemotherapybusiness.industryCarcinoma Ductal BreastCancerMiddle AgedInterim analysismedicine.diseaseNeoadjuvant TherapyCarcinoma LobularCarcinoma Intraductal NoninfiltratingOncologyDocetaxelChemotherapy AdjuvantFemalebusinessmedicine.drugEpirubicinEuropean Journal of Cancer
researchProduct

Immunoglobulin Kappa C Predicts Overall Survival in Node-Negative Breast Cancer

2012

Background: Biomarkers of the immune system are currently not used as prognostic factors in breast cancer. We analyzedthe association of the B cell/plasma cell marker immunoglobulin kappa C (IGKC) and survival of untreated node-negative breast cancer patients.Material and Methods: IGKC expression was evaluated by immunostaining in a cohort of 335 node-negative breast cancer patients with a median follow-up of 152 months. The prognostic significance of IGKC for disease-free survival (DFS) and breast cancer-specific overall survival (OS) was evaluated with Kaplan-Meier survival analysis as well as univariate and multivariate Cox analysis adjusted for age at diagnosis, pT stage, histological g…

OncologyPathologyB CellsEpidemiology610 MedizinEstrogen receptorlcsh:MedicineMetastasis610 Medical sciencesBasic Cancer ResearchPathologyStage (cooking)lcsh:ScienceUnivariate analysisMultidisciplinaryHazard ratioObstetrics and GynecologyMiddle AgedImmunohistochemistryOncologyMedicineFemaleResearch Articlemedicine.medical_specialtyImmune CellsImmunoglobulinsBreast NeoplasmsDisease-Free SurvivalImmunoglobulin kappa-ChainsBreast cancerDiagnostic MedicineInternal medicineProgesterone receptorBreast CancermedicineHumansAntibody-Producing CellsSurvival analysisImmune Evasionbusiness.industrylcsh:RImmunitymedicine.diseaseConfidence intervalBiomarker EpidemiologyHumoral Immunitylcsh:QClinical ImmunologybusinessBiomarkersGeneral Pathology
researchProduct

Cognitive Performance and Psychological Distress in Breast Cancer Patients at Disease Onset

2019

ObjectiveMany cancer patients complain about cognitive dysfunction. While cognitive deficits have been attributed to the side effects of chemotherapy, there is evidence for impairment at disease onset, prior to cancer-directed therapy. Further debated issues concern the relationship between self-reported complaints and objective test performance and the role of psychological distress.MethodWe assessed performance on neuropsychological tests of attention and memory and obtained estimates of subjective distress and quality of life in 27 breast cancer patients and 20 healthy controls. Testing in patients took place shortly after the initial diagnosis, but prior to subsequent therapy.ResultsWhi…

memorybreast cancerlcsh:Psychologycognitive functionspsychological distresslcsh:BF1-990attentionFrontiers in Psychology
researchProduct